ACTG A5164(V 20)-ANTIRETROVIRAL THERAPY FOR HIV-INFECTED ADULTS W/ACUTE OIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是了解在患者正在接受OI(机会性感染)或BI(细菌感染)治疗时，还是等到OI或BI治疗完毕后，立即开始抗击艾滋病毒的药物是更好的做法。目前尚不清楚艾滋病毒药物是否会导致副作用，从而使OI或BI等重病患者的问题恶化。这项研究的另一个目的是比较HIV药物在OI或BI期间或之后开始使用时的安全性和有效性。这项子研究的目的是比较患者在接受呼吸道感染治疗时和停止治疗呼吸道感染后血液中一些艾滋病毒药物的水平。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this study to learn whether it is better to start drugs that fight HIV right away, while a patient are being treated for an OI(opportunistic infection) or BI(bacterial infection), or wait until after the OI or BI has been treated. It is not known whether the HIV drugs cause side effects that could worsen the problems for seriously ill people such as those with OI or BI. Another purpose of this study is to compare the safety and effectiveness of the HIV drugs when started during or after an OI or BI. The purpose of the substudy is to compare the levels of some of the HIV drugs in the blood while a patient is receiving treatment for a respiratory infection and after they have stopped treatment for the respiratory infection.